NCT04095182 - Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions

Partial-onset Seizures With or Without Secondary Generalisation

Interventions

DRUG

Zebinix 400mg

Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)

DRUG

Placebo for Zebinix 400mg

"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"

DRUG

Zebinix 800mg

Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\~11)

DRUG

Placebo for Zebinix 800mg

"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"

DRUG

Zebinix 1600mg

Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)

DRUG

Placebo for Zebinix 1600mg

"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"

Trial Locations (1)

Whan In Pharm., Seoul

All Listed Sponsors

lead

Whanin Pharmaceutical Company

INDUSTRY